The neuroprotective effects of caffeine in neurodegenerative diseases.
Identifieur interne : 000010 ( Main/Exploration ); précédent : 000009; suivant : 000011The neuroprotective effects of caffeine in neurodegenerative diseases.
Auteurs : Mahshad Kolahdouzan [Canada] ; Mazen J. Hamadeh [Canada]Source :
- CNS neuroscience & therapeutics [ 1755-5949 ] ; 2017.
Abstract
Caffeine is the most widely used psychostimulant in Western countries, with antioxidant, anti-inflammatory and anti-apoptotic properties. In Alzheimer's disease (AD), caffeine is beneficial in both men and women, in humans and animals. Similar effects of caffeine were observed in men with Parkinson's disease (PD); however, the effect of caffeine in female PD patients is controversial due to caffeine's competition with estrogen for the estrogen-metabolizing enzyme, CYP1A2. Studies conducted in animal models of amyotrophic lateral sclerosis (ALS) showed protective effects of A2A R antagonism. A study found caffeine to be associated with earlier age of onset of Huntington's disease (HD) at intakes >190 mg/d, but studies in animal models have found equivocal results. Caffeine is protective in AD and PD at dosages equivalent to 3-5 mg/kg. However, further research is needed to investigate the effects of caffeine on PD in women. As well, the effects of caffeine in ALS, HD and Machado-Joseph disease need to be further investigated. Caffeine's most salient mechanisms of action relevant to neurodegenerative diseases need to be further explored.
DOI: 10.1111/cns.12684
PubMed: 28317317
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000024
- to stream PubMed, to step Curation: 000024
- to stream PubMed, to step Checkpoint: 000024
- to stream Ncbi, to step Merge: 002245
- to stream Ncbi, to step Curation: 002245
- to stream Ncbi, to step Checkpoint: 002245
- to stream Main, to step Merge: 000010
- to stream Main, to step Curation: 000010
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The neuroprotective effects of caffeine in neurodegenerative diseases.</title><author><name sortKey="Kolahdouzan, Mahshad" sort="Kolahdouzan, Mahshad" uniqKey="Kolahdouzan M" first="Mahshad" last="Kolahdouzan">Mahshad Kolahdouzan</name><affiliation wicri:level="1"><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Hamadeh, Mazen J" sort="Hamadeh, Mazen J" uniqKey="Hamadeh M" first="Mazen J" last="Hamadeh">Mazen J. Hamadeh</name><affiliation wicri:level="1"><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28317317</idno><idno type="pmid">28317317</idno><idno type="doi">10.1111/cns.12684</idno><idno type="wicri:Area/PubMed/Corpus">000024</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000024</idno><idno type="wicri:Area/PubMed/Curation">000024</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000024</idno><idno type="wicri:Area/PubMed/Checkpoint">000024</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000024</idno><idno type="wicri:Area/Ncbi/Merge">002245</idno><idno type="wicri:Area/Ncbi/Curation">002245</idno><idno type="wicri:Area/Ncbi/Checkpoint">002245</idno><idno type="wicri:Area/Main/Merge">000010</idno><idno type="wicri:Area/Main/Curation">000010</idno><idno type="wicri:Area/Main/Exploration">000010</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The neuroprotective effects of caffeine in neurodegenerative diseases.</title><author><name sortKey="Kolahdouzan, Mahshad" sort="Kolahdouzan, Mahshad" uniqKey="Kolahdouzan M" first="Mahshad" last="Kolahdouzan">Mahshad Kolahdouzan</name><affiliation wicri:level="1"><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Hamadeh, Mazen J" sort="Hamadeh, Mazen J" uniqKey="Hamadeh M" first="Mazen J" last="Hamadeh">Mazen J. Hamadeh</name><affiliation wicri:level="1"><nlm:affiliation>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Kinesiology and Health Science, Faculty of Health, York University, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author></analytic><series><title level="j">CNS neuroscience & therapeutics</title><idno type="eISSN">1755-5949</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Caffeine is the most widely used psychostimulant in Western countries, with antioxidant, anti-inflammatory and anti-apoptotic properties. In Alzheimer's disease (AD), caffeine is beneficial in both men and women, in humans and animals. Similar effects of caffeine were observed in men with Parkinson's disease (PD); however, the effect of caffeine in female PD patients is controversial due to caffeine's competition with estrogen for the estrogen-metabolizing enzyme, CYP1A2. Studies conducted in animal models of amyotrophic lateral sclerosis (ALS) showed protective effects of A2A R antagonism. A study found caffeine to be associated with earlier age of onset of Huntington's disease (HD) at intakes >190 mg/d, but studies in animal models have found equivocal results. Caffeine is protective in AD and PD at dosages equivalent to 3-5 mg/kg. However, further research is needed to investigate the effects of caffeine on PD in women. As well, the effects of caffeine in ALS, HD and Machado-Joseph disease need to be further investigated. Caffeine's most salient mechanisms of action relevant to neurodegenerative diseases need to be further explored.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Kolahdouzan, Mahshad" sort="Kolahdouzan, Mahshad" uniqKey="Kolahdouzan M" first="Mahshad" last="Kolahdouzan">Mahshad Kolahdouzan</name></noRegion><name sortKey="Hamadeh, Mazen J" sort="Hamadeh, Mazen J" uniqKey="Hamadeh M" first="Mazen J" last="Hamadeh">Mazen J. Hamadeh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000010 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000010 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28317317
|texte= The neuroprotective effects of caffeine in neurodegenerative diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28317317" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |